ATE226819T1 - Arzneizubereitungen für piperidinalkanolderivate - Google Patents

Arzneizubereitungen für piperidinalkanolderivate

Info

Publication number
ATE226819T1
ATE226819T1 AT96905292T AT96905292T ATE226819T1 AT E226819 T1 ATE226819 T1 AT E226819T1 AT 96905292 T AT96905292 T AT 96905292T AT 96905292 T AT96905292 T AT 96905292T AT E226819 T1 ATE226819 T1 AT E226819T1
Authority
AT
Austria
Prior art keywords
canolder
piperidine
derivatives
medicinal preparations
medicinal
Prior art date
Application number
AT96905292T
Other languages
English (en)
Inventor
Thomas T Ortyl
Paul F Skultety
Kristen C Mitchell
Deepak S Phadke
Faraneh Attarchi
Marguerite L Pierce
Aaron W Schoeneman
Joseph M Schnitz
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27015322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE226819(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE226819T1 publication Critical patent/ATE226819T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT96905292T 1995-02-28 1996-01-26 Arzneizubereitungen für piperidinalkanolderivate ATE226819T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39595295A 1995-02-28 1995-02-28
US55228795A 1995-12-12 1995-12-12
PCT/US1996/001253 WO1996026726A1 (en) 1995-02-28 1996-01-26 Pharmaceutical composition for piperidinoalkanol compounds

Publications (1)

Publication Number Publication Date
ATE226819T1 true ATE226819T1 (de) 2002-11-15

Family

ID=27015322

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96905292T ATE226819T1 (de) 1995-02-28 1996-01-26 Arzneizubereitungen für piperidinalkanolderivate

Country Status (22)

Country Link
US (9) US5738872A (de)
EP (1) EP0812195B1 (de)
JP (3) JP4105762B2 (de)
KR (1) KR100405116B1 (de)
CN (1) CN1090935C (de)
AR (1) AR003929A1 (de)
AT (1) ATE226819T1 (de)
AU (1) AU701042B2 (de)
CA (1) CA2213700C (de)
CL (1) CL2004000317A1 (de)
DE (1) DE69624559T2 (de)
DK (1) DK0812195T3 (de)
ES (1) ES2181868T3 (de)
FI (1) FI973518A0 (de)
HU (1) HUP9802086A3 (de)
IL (1) IL117237A (de)
MX (1) MX9706449A (de)
NO (2) NO325760B1 (de)
NZ (1) NZ302926A (de)
PT (1) PT812195E (de)
TW (1) TW460284B (de)
WO (1) WO1996026726A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2585705C (en) 1994-05-18 2012-04-17 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
PT812195E (pt) * 1995-02-28 2003-03-31 Aventis Pharma Inc Composicao farmaceutica para compostos de piperidinoalcanol
US7091183B1 (en) * 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
PT998272E (pt) * 1997-08-26 2003-09-30 Aventis Pharma Inc Composicao farmaceutica para combinacao do descongestionante piperidinoalcanol
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
DK0991415T3 (da) * 1997-12-22 2003-06-16 Schering Corp Faste, oralt indgivelige dosisformer for ribavirin og fremgangsmåde til fremstilling af disse
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
HUP0600143A2 (en) * 2000-02-17 2006-10-28 Teva Pharma A stable pharmaceutical formulation comprising torsemide modification ii
US6613906B1 (en) 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
US8155096B1 (en) 2000-12-01 2012-04-10 Ipr Licensing Inc. Antenna control system and method
BR0207297A (pt) 2001-02-15 2005-04-19 King Pharmaceuticals Inc Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
US6569454B2 (en) * 2001-02-27 2003-05-27 Minh Van Nguyen Simple tablet compression using gelatin
EP1392303A4 (de) * 2001-04-09 2005-01-26 Teva Pharma Polymorphe von fexofenadin-hydrochlorid
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
PT1414453E (pt) * 2001-07-31 2008-05-29 Texcontor Ets Polimorfo de cloridrato de fexofenadina
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
AU2003243191B2 (en) * 2002-05-02 2007-09-20 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
AU2003248657A1 (en) * 2002-06-10 2003-12-22 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
CA2477221A1 (en) * 2003-01-03 2004-07-29 Minh Nguyen Simple tablet compression using gelatin
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
US20050065183A1 (en) * 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
EP1628959A2 (de) * 2004-04-26 2006-03-01 Teva Pharmaceutical Industries Ltd Polymorphe form xvi von fexofenadine-hydrochlorid
US20060148851A1 (en) * 2004-09-28 2006-07-06 Shlomit Wizel Fexofenadine crystal form and processes for its preparation thereof
EP1729735B1 (de) * 2004-11-10 2007-06-27 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von komprimierten festen dosierungsformen, das gut zur verwendung mit schlecht wasserlöslichen arzneistoffen geeignet ist, und danach hergestellte komprimierte feste dosierungsformen
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
JP4733120B2 (ja) 2005-05-26 2011-07-27 大日本住友製薬株式会社 医薬品組成物
KR100735904B1 (ko) 2005-08-02 2007-07-04 주식회사 드림파마 한방 건조엑스 함유 정제 조성물 및 그를 이용한 한방건조엑스 함유 정제의 제조방법
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
WO2007052310A2 (en) * 2005-11-03 2007-05-10 Morepen Laboratories Limited Polymorphs of fexofenadine hydrochloride and process for their preparation
CN103751186B (zh) * 2006-04-05 2016-08-24 欧科生医股份有限公司 药物制剂：8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮的盐及用其治疗的方法
CA2678367C (en) * 2007-03-02 2014-07-08 Farnam Companies, Inc. Sustained release compositions using wax-like materials
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
AU2010256450B2 (en) * 2009-06-05 2014-09-18 Arthrocare Corporation Systems and devices for providing therapy of an anatomical structure
CN102573475B (zh) 2009-08-14 2016-01-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
FR2959130A1 (fr) 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
FR2999937B1 (fr) 2012-12-21 2015-01-09 Sanofi Sa Unite solide a haute teneur en fexofenadine et son procede de preparation
AR094761A1 (es) 2013-02-14 2015-08-26 Sanofi Sa Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma
WO2015001478A1 (en) 2013-07-01 2015-01-08 Aventis Pharmaceuticals Inc. Liquid pharmaceutical composition for oral administration comprising fexofenadine
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
EP3002005A1 (de) * 2014-09-30 2016-04-06 Molkerei Meggle Wasserburg GmbH & Co. Kg Direktkomprimierter Hilfsstoff auf Basis von Lactose, Cellulose und Stärke
KR101825041B1 (ko) * 2016-04-07 2018-02-02 주식회사 바이오솔루션 물질 p를 포함하는 상처치유용 약학 조성물

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878217A (en) * 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
US3806526A (en) * 1972-01-28 1974-04-23 Richardson Merrell Inc 1-aroylalkyl-4-diphenylmethyl piperidines
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
DE2348334C2 (de) * 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US3966949A (en) * 1973-10-12 1976-06-29 Richardson-Merrell Inc. Pharmaceutical compositions and preparing same
US3941795A (en) * 1974-02-08 1976-03-02 Richardson-Merrell Inc. α-ARYL-4-SUBSTITUTED PIPERIDINOALKANOL DERIVATIVES
FR2408345A1 (fr) * 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4285957A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
US4285958A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4254130A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4493528A (en) * 1980-04-11 1985-01-15 Board Of Trustees Of The Leland Stanford Junior University Fiber optic directional coupler
EP0111114A3 (de) * 1982-11-06 1985-10-09 Telefonbau und Normalzeit GmbH Schaltungsanordnung für eine Fernsprechvermittlungsanlage, insbesondere Fernsprechnebenstellenanlage mit zusätzlichem Datenverkehr
GB8613811D0 (en) * 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
DK164642C (da) * 1984-08-30 1992-12-14 Merrell Dow Pharma Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler
US4639458A (en) * 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
US4916163A (en) * 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
US4963540A (en) * 1986-04-16 1990-10-16 Maxson Wayne S Method for treatment of premenstrual syndrome
SE8603812D0 (sv) * 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
DE3720493A1 (de) * 1987-06-20 1989-01-26 Nattermann A & Cie Arzneizubereitungen mit mikronisierten ebselen-kristallen
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
AR240018A1 (es) * 1987-10-07 1990-01-31 Merrell Pharma Inc Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol.
CN1053570C (zh) * 1987-10-07 2000-06-21 默尔多药物公司 哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
SE8804173A0 (sv) * 1988-11-18 1990-05-19 Lim Johan Ab Insektsfångare
AR245888A1 (es) * 1989-01-23 1994-03-30 Merrell Pharma Inc Procedimiento para la preparacion de una composicion farmaceutica liquida de derivados de piperidinoalcanol.
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
US5271944A (en) * 1991-04-05 1993-12-21 Biofor, Ltd. Pharmacologically enhanced formulations
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
IT1250421B (it) * 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5516803A (en) * 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
DE69227257T2 (de) * 1991-12-12 1999-03-25 Glaxo Group Ltd Arzneimittel
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
EP0635004B1 (de) 1992-04-10 2002-07-17 Merrell Pharmaceuticals Inc. 4-diphenylmethylpiperidine und verfahren zu ihrer herstellung
EP0639976B1 (de) * 1992-05-11 2000-07-26 Merrell Pharmaceuticals Inc. Verwendung von terfenadin-derivaten als antihistaminika in leberkranken patienten
US5429825A (en) * 1992-06-26 1995-07-04 Mcneil-Ppc, Inc. Rotomelt granulation
WO1994003170A1 (en) * 1992-08-03 1994-02-17 Sepracor Inc. Terfenadine metabolites and their optically pure isomers for treating allergic disorders
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
DK1026147T3 (da) * 1993-06-24 2004-03-22 Albany Molecular Res Inc Forbindelser, der er anvendelige som mellemprodukter i fremstillingen af piperidinderivater
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
CA2128821A1 (en) * 1993-07-27 1995-01-28 Dilip J. Gole Freeze-dried pharmaceutical dosage form and process for separation thereof
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
US5895664A (en) * 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
CA2585705C (en) * 1994-05-18 2012-04-17 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
PT812195E (pt) * 1995-02-28 2003-03-31 Aventis Pharma Inc Composicao farmaceutica para compostos de piperidinoalcanol
US5574045A (en) * 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
ATE224721T1 (de) * 1997-08-14 2002-10-15 Aventis Pharma Inc Verfahren zur verbesserung der bioverfügbarkeit des fexofenadins und seiner derivate
US6451815B1 (en) * 1997-08-14 2002-09-17 Aventis Pharmaceuticals Inc. Method of enhancing bioavailability of fexofenadine and its derivatives
PT998272E (pt) * 1997-08-26 2003-09-30 Aventis Pharma Inc Composicao farmaceutica para combinacao do descongestionante piperidinoalcanol

Also Published As

Publication number Publication date
CN1176599A (zh) 1998-03-18
US20070249671A1 (en) 2007-10-25
NO973938D0 (no) 1997-08-27
AR003929A1 (es) 1998-09-30
CL2004000317A1 (es) 2005-01-21
US8129408B2 (en) 2012-03-06
US5738872A (en) 1998-04-14
US20100021547A1 (en) 2010-01-28
AU701042B2 (en) 1999-01-21
TW460284B (en) 2001-10-21
NO973938L (no) 1997-10-28
DE69624559D1 (de) 2002-12-05
PT812195E (pt) 2003-03-31
JP4177787B2 (ja) 2008-11-05
DE69624559T2 (de) 2003-07-10
CA2213700C (en) 2002-04-02
HUP9802086A2 (hu) 1999-01-28
KR100405116B1 (ko) 2004-02-05
JP4105762B2 (ja) 2008-06-25
IL117237A (en) 2001-01-11
ES2181868T3 (es) 2003-03-01
EP0812195B1 (de) 2002-10-30
JPH11501028A (ja) 1999-01-26
WO1996026726A1 (en) 1996-09-06
US5855912A (en) 1999-01-05
KR19980702575A (ko) 1998-07-15
CA2213700A1 (en) 1996-09-06
NZ302926A (en) 1998-10-28
FI973518L (fi) 1997-08-27
JP2004292459A (ja) 2004-10-21
DK0812195T3 (da) 2003-03-03
FI973518A7 (fi) 1997-08-27
HUP9802086A3 (en) 2001-02-28
MX9706449A (es) 1997-11-29
NO325760B1 (no) 2008-07-14
US6113942A (en) 2000-09-05
FI973518A0 (fi) 1997-08-27
IL117237A0 (en) 1996-06-18
CN1090935C (zh) 2002-09-18
JP2008266347A (ja) 2008-11-06
NO20065390L (no) 1997-10-28
US20020106405A1 (en) 2002-08-08
EP0812195A1 (de) 1997-12-17
AU4909896A (en) 1996-09-18
US5932247A (en) 1999-08-03
US20010022973A1 (en) 2001-09-20
US20030203020A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
ATE226819T1 (de) Arzneizubereitungen für piperidinalkanolderivate
FI973243L (fi) Uusi farmaseuttinen yhdistelmä
DE69522717D1 (de) Chinazolinderivate
DE69611361D1 (de) Chinazolin-derivate
NO974103D0 (no) Arylsulfonylaminohydroksamsyre-derivater
DE69625368D1 (de) Schweisshemmende deodorierende präparaten
DE69610698D1 (de) Chinazolin-derivate
NO965343D0 (no) Rålegemiddelholdig for
ATE199150T1 (de) Diphenylmethylenpiperidin-derivate
NO964667D0 (no) Purin-6-on-derivater
BR9610214A (pt) Compostos farmacéuticos
DE69601527D1 (de) Pyrrolylbenzimidazol-Derivate
ATA100695A (de) Prothrombin-derivate
DE69628200D1 (de) Diarylalkenylamin-derivate
DE69627830D1 (de) Pyrazol-derivate
FI973229A7 (fi) Uusi farmaseuttinen koostumus
ATE202093T1 (de) 4-amino-benzoylguanidin-derivate
FI973230L (fi) Uusi farmaseuttinen formulaatio
DE59610106D1 (de) Fluorbenzylether-Derivate
ATE177102T1 (de) Chromanderivate
DE69624122D1 (de) Aza-anthracyclinone-derivate
NO965448D0 (no) Farmasöytiske forbindelser
DE59607055D1 (de) 4-Mercapto-benzoylguanidin-Derivate
DE69620514D1 (de) 5-aminoflavon-derivate
ATA45796A (de) Lysin-prolin-derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0812195

Country of ref document: EP

RZN Patent revoked